Volume 95 Issue 6 | p. 12 | Concentrates
Issue Date: February 6, 2017

Drugmakers fund research at U.K. schools

Department: Business
Keywords: drug development, Oxford, Novo Nordisk, diabetes
[+]Enlarge
A rendering of Novo’s planned research center at Oxford.
Credit: Novo Nordisk
A rendering of Novo’s planned research center at Oxford.
 
A rendering of Novo’s planned research center at Oxford.
Credit: Novo Nordisk

Two drug companies have formed collaborations with leading U.K. universities. Novo Nordisk and the University of Oxford are joining to discover novel approaches for treating type 2 diabetes. As part of the agreement Novo will establish a research center at the university that will employ up to 100 scientists. The Danish firm expects to invest about $150 million in the initiative over 10 years. The partners say they seek cross-fertilization of ideas between academics and Novo researchers. Novo already funds 32 fellows at the university as a result of a 2013 pact. Separately, Heptares Therapeutics will fund efforts by Anthony Davenport’s group at the University of Cambridge to discover molecules that target the apelin receptor, a G protein-coupled receptor implicated in a range of cardiovascular diseases.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment